1
|
Ou S, Tancrède-Bohin E, Alexandre M, Ingen-Housz-Oro S, Castel M, Debarbieux S, Duvert-Lehembre S, Konstantinou MP, Abasq C, Berthin C, Couzan C, Lepelletier C, Jelti L, Bouteiller J, Calugareanu A, Véron M, Caux F, Joly P, Thomas B, Viguier M. Efficacy and safety of anti-COVID-19 vaccination in patients with autoimmune blistering diseases: A French national study. J Am Acad Dermatol 2024; 90:204-208. [PMID: 37769901 DOI: 10.1016/j.jaad.2023.08.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 08/16/2023] [Accepted: 08/20/2023] [Indexed: 10/03/2023]
Affiliation(s)
- Sokounthie Ou
- Department of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne Ardenne, Reims, France
| | - Emmanuelle Tancrède-Bohin
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Marina Alexandre
- Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM UMR1125, Bobigny, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri-Mondor University Hospital, Assistance Publique - Hôpitaux de Paris, University Paris Est Créteil, EpidermE, Créteil, France
| | - Marion Castel
- Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM U1234, Normandie University, Rouen, France
| | - Sébastien Debarbieux
- Department of Dermatology, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France
| | - Sophie Duvert-Lehembre
- Department of Dermatology, Lille University Hospital, Lille, France; Department of Dermatology, Dunkerque Hospital, Dunkerque, France
| | | | - Claire Abasq
- Department of Dermatology, Augustin-Morvan Hospital, Brest, France
| | | | - Caroline Couzan
- Department of Dermatology, Saint-Étienne Hospital, Saint-Étienne, France
| | - Clémence Lepelletier
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Lamia Jelti
- Department of Dermatology, Henri-Mondor University Hospital, Assistance Publique - Hôpitaux de Paris, University Paris Est Créteil, EpidermE, Créteil, France
| | - Julie Bouteiller
- Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM U1234, Normandie University, Rouen, France
| | | | - Marie Véron
- Department of Dermatology, Lille University Hospital, Lille, France
| | - Frédéric Caux
- Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM UMR1125, Bobigny, France
| | - Pascal Joly
- Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM U1234, Normandie University, Rouen, France
| | - Bérenger Thomas
- Department of Epidemiology, Faculty of Medicine, Sorbonne University, Paris, France
| | - Manuelle Viguier
- Department of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne Ardenne, Reims, France.
| |
Collapse
|
2
|
Mauguen C, Maruani A, Barbarot S, Abasq C, Martin L, Herbert J, Goronflot T, Gourraud PA, Happe A, Descatha A, Chrétien JM, Beuchée A, Adamski H, Dupuy A, Bouzillé G, Oger E, Droitcourt C. Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014-2021 French Ouest DataHub. Ann Dermatol Venereol 2023; 150:189-194. [PMID: 37225615 DOI: 10.1016/j.annder.2023.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 12/08/2022] [Accepted: 03/24/2023] [Indexed: 05/26/2023]
Abstract
BACKGROUND The factors associated with early relapse of infantile haemangioma (IH) after a first course of treatment with oral propranolol for at least six months (initiated after the marketing authorization had been granted) have not previously been investigated. OBJECTIVES To identify factors associated with the risk of early relapse in children with IH treated with oral propranolol according to the current prescribing guidelines. METHODS We performed a multicentre, retrospective, case-control study, using the Ouest Data Hub database. All children treated for at least 6 months with oral propranolol for IH between 31 June 2014 and 31 December 2021, and with a follow-up visit at least three months after treatment discontinuation were included. A case was defined as relapse of IH within three months of treatment discontinuation; each case was matched for age at treatment initiation and for centre, with four (relapse-free) controls. The association between relapse and treatment or IH characteristics was expressed as an odds ratio (OR) from univariate and multivariate conditional logistic regressions. RESULTS A total of 225 children were included. Of these, 36 (16%) relapsed early. In a multivariate analysis, a deep IH component was a risk factor for early relapse [OR = 8.93; 95%CI: 1.0-78.9, p = 0.05]. A propranolol dosage level of less than 3 mg/kg/day protected against early relapse [OR = 0.11; 95%CI: 0.02-0.7, p = 0.02]. Tapering before propranolol discontinuation was not associated with a lower risk of early relapse. CONCLUSION The risk factors for late and early relapse are probably different. Investigation of the risk factors for early vs. late IH relapse is now warranted.
Collapse
Affiliation(s)
- C Mauguen
- Department of Dermatology, CHU Rennes, 35000 Rennes, France.
| | - A Maruani
- University of Tours, INSERM 1246-SPHERE, Department of Dermatology, Tours University Hospital, F-37000 Tours, France; Dermatology Department and Reference Centre for Rare Diseases and Vascular Malformations (MAGEC), Tours University Hospital, 37000 Tours, France
| | - S Barbarot
- Department of Dermatology, CHU Nantes and INSERM CIC 004, 44000 Nantes, France
| | - C Abasq
- Department of Dermatology, Brest University Hospital, 29200 Brest, France
| | - L Martin
- Department of Dermatology, Angers University Hospital, 4, rue Larrey, 49933 Angers, France
| | - J Herbert
- Clinical Data Centre, Public Health and Prevention Unit, Tours University Hospital, 37044 Tours, France
| | - T Goronflot
- Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, INSERM, CIC 1413, 44000 Nantes, France
| | - P-A Gourraud
- Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, INSERM, CIC 1413, 44000 Nantes, France
| | - A Happe
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| | - A Descatha
- Univ Angers, CHU Angers, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 49000 Angers, France
| | - J-M Chrétien
- Clinical Research Department, Angers University Hospital, 49000 Angers, France
| | - A Beuchée
- Department of Neonatalogy, Rennes University Hospital, Rennes, France
| | - H Adamski
- Department of Dermatology, CHU Rennes, 35000 Rennes, France
| | - A Dupuy
- Department of Dermatology, CHU Rennes, 35000 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| | - G Bouzillé
- Univ Rennes, CHU Rennes, Inserm, LTSI - UMR 1099, 35000 Rennes, France
| | - E Oger
- Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Department of Clinical Pharmacology, Rennes University Hospital, 35000 Rennes, France
| | - C Droitcourt
- Department of Dermatology, CHU Rennes, 35000 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| |
Collapse
|
3
|
Orly J, Bisdorff A, Fraissenon A, Joly A, Boulouis G, Guibaud L, Tavernier E, Mallet S, Marcelin C, Miquel J, Martin L, Droitcourt C, Gusdorf L, Abasq C, Dadban A, Chiaverini C, Vabres P, Herbreteau D, Boccara O, Wassef M, Maruani A. Intramuscular capillary-type hemangioma: Diagnosis, treatment, and outcomes. A French multicentric retrospective study of 66 cases. Eur J Radiol 2023; 165:110962. [PMID: 37423018 DOI: 10.1016/j.ejrad.2023.110962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 07/02/2023] [Accepted: 07/03/2023] [Indexed: 07/11/2023]
Abstract
PURPOSE Intramuscular capillary-type hemangiomas (ICTHs) are rare entities, belonging to the group of intramuscular "hemangiomas." The diagnosis remains challenging. We aimed to assess the diagnostic criteria, treatments and outcomes of ICTHs. METHODS This retrospective study collected all cases of ICTH followed up in 9 French hospital centers, reviewed by an adjudication expert group. RESULTS Among 133 patients screened, 66 with ICTH were included. The median age of patients at diagnosis was 28.0 years, interquartile range (21.0---36.0). The lesion, mainly presenting as a gradually increasing mass (83.9%), was painless (88.9%) and was located in the head and neck (42.4%). MRI (available in all cases) mainly revealed a well-delineated lesion, isointense to the muscle on T1-weighted images, with enhancement after contrast injection; hyperintense on T2-weighted images; and containing flow voids. Among the 66 cases, 59 exhibited typical ICTH features and 7 shared some imaging features with arteriovenous malformations. These latter were larger than typical ICTHs and more painful and appeared on imaging as less well delimited and more heterogeneous tissue masses, with larger tortuous afferent arteries, earlier draining vein opacification and mild arteriovenous shunting. We propose to name these lesions arteriovenous malformation (AVM)-like ICTH. Pathological reports were similar in typical and AVM-like ICTH, showing capillary proliferation with mainly small-size vessels, negative for GLUT-1 and positive for ERG, AML, CD31 and CD34, with low Ki67 proliferation index (<10%), and adipose tissue. The most frequent treatment for ICTH was complete surgical resection (17/47, 36.2%), preceded in some cases by embolization, which led to complete remission. CONCLUSIONS ICTH can be diagnosed on MRI when it is typical. Biopsy or angiography are required for atypical forms.
Collapse
Affiliation(s)
- Jordan Orly
- CHRU Tours, Department of Dermatology, Unit of Pediatric Dermatology, Tours, France; Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France
| | - Annouk Bisdorff
- Reference Center for Vascular Anomalies FAVA-multi, University Hospital of Lariboisière, Coordinator of the Constitutive Center for Superficial Arteriovenous Malformations in Children and Adults, AP-HP, Department of Neuroradiology, Paris, France
| | - Antoine Fraissenon
- Service d'Imagerie, Consultation Multidisciplinaire des Angiomes, Centre de Compétence National Malformations Vasculaires Superficielles, Hôpital Femme Mère Enfant, Université Claude Bernard Lyon 1, Lyon-Bron, France; Service de Radiologie Mère-Enfant, Hôpital Nord, Saint-Etienne, France; CREATIS, UMR 5220, U1294 Lyon, France
| | - Aline Joly
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France; CHRU Tours, Department of Maxillo-facial Surgery, Tours, France
| | - Grégoire Boulouis
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France; CHRU Tours, Department of Neuroradiology and Interventional Radiology, Tours, France
| | - Laurent Guibaud
- Service d'Imagerie, Consultation Multidisciplinaire des Angiomes, Centre de Compétence National Malformations Vasculaires Superficielles, Hôpital Femme Mère Enfant, Université Claude Bernard Lyon 1, Lyon-Bron, France
| | - Elsa Tavernier
- University of Tours, University of Nantes, INSERM 1246-SPHERE, Tours, France; CHRU Tours, Clinical Investigation Center INSERM 1415, Tours, France
| | - Stéphanie Mallet
- University Hospital Center of Marseille, Department of Dermatology, Marseille, France
| | - Clément Marcelin
- University Hospital Center of Bordeaux, Department of Radiology, Bordeaux, France
| | - Juliette Miquel
- University Hospital Center of La Réunion, Department of Pediatric Dermatology, Saint-Pierre, La Réunion, France
| | - Ludovic Martin
- University Hospital Center of Angers, Department of Dermatology, Angers, France
| | | | - Laurence Gusdorf
- University Hospital Center of Reims, Department of Dermatology, Reims, France
| | - Claire Abasq
- University Hospital Center of Brest, Department of Dermatology, Brest, France
| | - Ali Dadban
- University Hospital Center of Amiens, Department of Dermatology, Amiens, France
| | | | - Pierre Vabres
- University of Bourgogne, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Dijon, France
| | - Denis Herbreteau
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France; CHRU Tours, Department of Neuroradiology and Interventional Radiology, Tours, France
| | - Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Necker), University Hospital Necker-Enfants Malades, Paris, France
| | - Michel Wassef
- University Hospital of Lariboisière, AP-HP, Department of Pathology, Paris, France
| | - Annabel Maruani
- CHRU Tours, Department of Dermatology, Unit of Pediatric Dermatology, Tours, France; Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France; University of Tours, University of Nantes, INSERM 1246-SPHERE, Tours, France.
| |
Collapse
|
4
|
Cordel N, Flament J, Jouen F, Seta V, Tancrède-Bohin E, Dahan CP, Konstantinou MP, Dereure O, Quéreux G, Prost C, Bedane C, Debarbieux S, Lacour JP, Dompmartin A, Wierzbicka-Hainaut E, Villada IB, Oro SIH, Vabres P, Richard MA, Delaporte E, Pham-Ledard A, Leccia MT, Litrowski N, Michel C, Lagrange B, D'Incan M, Abasq C, Duvert-Lehembre S, Dupuy A, Alcaraz I, Breton-Guitarian AL, Lombart F, Estève E, Machet L, Del Giudice P, Fenot M, Belmondo T, Morin F, Guérin O, Benichou J, Tressières B, Joly P. Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis. J Eur Acad Dermatol Venereol 2023; 37:1207-1214. [PMID: 36802102 DOI: 10.1111/jdv.18973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 01/27/2023] [Indexed: 02/20/2023]
Abstract
BACKGROUND Adverse pregnancy outcomes (APO) occur in 35% of patients with pemphigoid gestationis (PG). No biological predictor of APO has been established yet. OBJECTIVES To assess a potential relationship between the occurrence of APO and the serum value of anti-BP180 antibodies at the time of PG diagnosis. METHODS Multicentre retrospective study conducted from January 2009 to December 2019 in 35 secondary and tertiary care centres. INCLUSION CRITERIA (i) diagnosis of PG according to clinical, histological and immunological criteria, (ii) ELISA measurement of anti-BP180 IgG antibodies determined at the time of PG diagnosis with the same commercial kit and (iii) obstetrical data available. RESULTS Of the 95 patients with PG included, 42 had one or more APO, which mainly corresponded to preterm birth (n = 26), intrauterine growth restriction (IUGR) (n = 18) and small weight for gestational age at birth (n = 16). From a ROC curve, we identified a threshold of 150 IU ELISA value as the most discriminating to differentiate between patients with or without IUGR, with 78% sensitivity, 55% specificity, 30% positive and 91% negative predictive value. The threshold >150 IU was confirmed using a cross-validation based on bootstrap resampling, which showed that the median threshold was 159 IU. Upon adjusting for oral corticosteroid intake and main clinical predictors of APO, an ELISA value of >150 IU was associated with the occurrence of IUGR (OR = 5.11; 95% CI: 1.48-22.30; p = 0.016) but not with any other APO. The combination of blisters and ELISA values higher than 150 IU led to a 2.4-fold higher risk of all-cause APO (OR: 10.90; 95% CI: 2.33-82.3) relative to patients with blisters but lower values of anti-BP180 antibodies (OR of 4.54; 95% CI 0.92-34.2). CONCLUSION These findings suggest that anti-BP180 antibody ELISA value in combination with clinical markers is helpful in managing the risk of APO, in particular IUGR, in patients with PG.
Collapse
Affiliation(s)
- Nadège Cordel
- Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Pointe-à-Pitre, Guadeloupe.,Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Rouen, France
| | - Jasmine Flament
- Department of Dermatology, Rouen University Hospital, Rouen, France
| | - Fabienne Jouen
- Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Rouen, France.,Department of Immunology and biotherapies, Rouen University Hospital, Rouen, France
| | - Vannina Seta
- Department of Dermatology, Cochin Hospital AP-HP, Paris, France
| | | | | | | | - Olivier Dereure
- Department of Dermatology, Saint-Eloi University Hospital, Montpellier, France
| | - Gaëlle Quéreux
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - Catherine Prost
- Department of Dermatology, Avicenne Hospital AP-HP, Bobigny, France
| | - Christophe Bedane
- Department of Dermatology, Limoges University Hospital, Limoges, France
| | | | | | - Anne Dompmartin
- Department of Dermatology, Caen University Hospital, Caen, France
| | | | | | - Saskia Ingen Housz Oro
- Department of Dermatology, Henri Mondor Hospital, AP-HP and Univ Paris Est Créteil, EpidermE, Créteil, France
| | - Pierre Vabres
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Marie-Aleth Richard
- Department of Dermatology, La Timone University Hospital APHM, Marseille, France
| | - Emmanuel Delaporte
- Department of Dermatology, UMR 7268 and North University Hospital APHM, Marseille, France
| | - Anne Pham-Ledard
- Department of Dermatology, University Hospital of Bordeaux, Saint-André Hospital, Bordeaux, France
| | - Marie-Thérèse Leccia
- Department of Dermatology, Allergology and Photobiology, Grenoble University Hospital, Grenoble, France
| | - Noémie Litrowski
- Department of Dermatology, Monod General Hospital, Le Havre, France
| | - Catherine Michel
- Department of Dermatology, Emile Muller Hospital, Mulhouse, France
| | | | - Michel D'Incan
- Department of Dermatology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Claire Abasq
- Department of Dermatology, Brest University Hospital, Brest, France
| | | | - Alain Dupuy
- Department of Dermatology, Rennes University Hospital, Rennes, France
| | - Isabelle Alcaraz
- Department of Infectious diseases and Travel, Gustave Dron Hospital, Tourcoing, France
| | | | - Florian Lombart
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - Eric Estève
- Department of Dermatology, Orléans Regional Hospital, Orléans, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | - Pascal Del Giudice
- Infectiology-Dermatology Unit, Intercommunal Hospital of Fréjus Saint Raphaël, Fréjus, France
| | - Marion Fenot
- Department of Dermatology, Departmental Hospital of Vendée, La Roche-sur-Yon, France
| | - Thibaut Belmondo
- Department of Immunology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Florence Morin
- Department of Immunology, Saint-Louis Hospital AP-HP, Paris, France
| | - Olivia Guérin
- Department of Biostatistics, Rouen University Hospital
| | - Jacques Benichou
- Department of Biostatistics, Rouen University Hospital.,Univ Rouen Normandie, IRIB, Inserm U1219, Rouen, France
| | - Benoît Tressières
- Centre d'Investigation Clinique Antilles Guyane, INSERM CIC 1424, Pointe-à-Pitre, Guadeloupe
| | - Pascal Joly
- Univ Rouen Normandie, FOCIS Center of Excellence PAn'THER, Rouen, France.,Department of Dermatology, Rouen University Hospital, Rouen, France
| | | |
Collapse
|
5
|
Eveillard LA, Quartier P, Ouldali N, Bader-Meunier B, Aeschlimann F, Abasq C, Ballot C, Bouric P, Desdoits A, Dumaine C, Galeotti C, Hentgen V, Lefevre-Utile A, Chausset A, Hubiche T, Kupfer-Bessaguet I, Leclerq-Mercier S, Mallet S, Melki I, Merlin E, Miquel J, Piram M, Talmud D, Garcelon N, Vinit C, Welfringer A, Bourrat E, Meinzer U. Association of atypical skin manifestations at the onset of systemic juvenile idiopathic arthritis with difficult-to-treat disease: A retrospective multicenter study. J Am Acad Dermatol 2022; 87:1425-1428. [PMID: 35963289 DOI: 10.1016/j.jaad.2022.07.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2022] [Revised: 07/09/2022] [Accepted: 07/15/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Laurye-Anne Eveillard
- General Pediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE) Robert Debré University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France; Centre de Recherche sur l'Inflammation, INSERM, UMR 1149, Université Paris Cité, Paris, France
| | - Pierre Quartier
- Pediatric Immunology-Hematology and Rheumatology Unit, Rare Disease Reference Centre (RAISE), IMAGINE Institute, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Naim Ouldali
- General Pediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE) Robert Debré University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Brigitte Bader-Meunier
- Pediatric Immunology-Hematology and Rheumatology Unit, Rare Disease Reference Centre (RAISE), IMAGINE Institute, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Florence Aeschlimann
- Pediatric Immunology-Hematology and Rheumatology Unit, Rare Disease Reference Centre (RAISE), IMAGINE Institute, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Claire Abasq
- Department of Dermatology, Brest University Hospital, Brest, France
| | - Claire Ballot
- Pediatric hematology, Jean-Minjoz Hospital, Besançon, France
| | - Pauline Bouric
- CH Auray-Vannes, Hôpital Bretagne Atlantique, Paediatric Department, Boulevard du Général Guillaudot, Vannes Cedex, France
| | - Alexandra Desdoits
- Department of Pediatric Surgery, CHU de Caen, AutoImmune and Systemic Diseases in Children (RAISE), Reference Centre for Autoinflammatory Disorders (CEREMAI), Caen, France
| | - Cécile Dumaine
- General Pediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE) Robert Debré University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Caroline Galeotti
- Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory diseases and amyloidosis (CEREMAIA), Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Université Paris Saclay, Le Kremlin-Bicêtre, France
| | - Véronique Hentgen
- Reference Centre for Autoinflammatory Disorders (CEREMAI) Centre Hospitalier de Versailles, Le Chesnay Cedex, France
| | - Alain Lefevre-Utile
- Université de Paris, INSERM, U976 HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Assistance Puplique-Hôpitaux de Paris (APHP), General Pediatrics and Pediatric Emergency Department, Jean Verdier Hospital, Bondy, France
| | - Aurélie Chausset
- Department of Pediatrics, Clermont Ferrand University Hospital, Clermont-Ferrand, France; CRECHE Unit, INSERM, CIC 1405, Clermont Auvergne University, Clermont-Ferrand, France
| | - Thomas Hubiche
- Department of Dermatology, Université Côte d'Azur, Nice, France
| | | | - Stéphanie Leclerq-Mercier
- Pathology Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Isabelle Melki
- General Pediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE) Robert Debré University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Etienne Merlin
- Department of Pediatrics, Clermont Ferrand University Hospital, Clermont-Ferrand, France; CRECHE Unit, INSERM, CIC 1405, Clermont Auvergne University, Clermont-Ferrand, France
| | - Juliette Miquel
- Department of Pediatrics, CHU Reunion Saint-Pierre, Reunion Island, France
| | - Maryam Piram
- Department of Pediatrics, Pediatric Dermatology Unit, CHI Sainte Justine, CHU Sainte Justine Research Centre, University of Montreal, Montreal, Quebec, Canada
| | - Deborah Talmud
- Pediatric Department, Centre Hospitalier Régional d'Orléans, Orléans, France
| | - Nicolas Garcelon
- Institut Imagine, Centre de Recherche des Cordeliers, Equipe 22, UMR 1138, INSERM, Paris, France
| | - Caroline Vinit
- General Pediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE) Robert Debré University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Anne Welfringer
- Department of Dermatology, Reference Centre for Genodermatoses and Rare Skin Disease (MAGEC), Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Emmanuelle Bourrat
- Department of Dermatology, Robert Debré University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Ulrich Meinzer
- General Pediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE) Robert Debré University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France; Centre de Recherche sur l'Inflammation, INSERM, UMR 1149, Université Paris Cité, Paris, France.
| | | | | |
Collapse
|
6
|
Sanchez A, Mahe E, Miquel J, Abasq C, Phan A, Mazereeuw‐Hautier J, Lemille J, Maruani A, Bonniaud B, Plantin P, Mallet S, Martin H, Hubiche T, Chiaverini C, Lacour J. Perialar intertrigo in children and adolescents: A multicenter prospective study of 41 cases. Pediatr Dermatol 2022; 39:702-707. [PMID: 35699273 PMCID: PMC9796429 DOI: 10.1111/pde.15036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 05/01/2022] [Indexed: 01/01/2023]
Abstract
BACKGROUND/OBJECTIVES We observed isolated cases of perialar intertrigo in children and teenagers that did not appear to correspond to any known clinical entity. The objective of this study was to describe the clinical features of this dermatosis and the clinical characteristics of the patients. METHODS We conducted a prospective, multicenter cohort study in France from August 2017 to November 2019. All the patients under 18 years of age with chronic perinasal intertrigo were included. A standardized questionnaire detailing the clinical characteristics of the patients and the description of the intertrigo. If possible, a Wood's lamp examination of the intertrigo was done. RESULTS Forty-one patients were included (25 boys and 16 girls, average age: 12.1 years). Intertrigo was bilateral in 38 patients (93%). The majority of patients had no symptoms (54%). Pruritus was present in 39% of cases. Orange red follicular fluorescence was present in the perialar region on Wood's light examination in 78% of cases with active fluorescence. The presumptive diagnoses suggested by the investigators were acne (24.4%), seborrheic dermatitis (19.5%), rosacea (9.8%), psoriasis (9.8%) and perioral dermatitis (7.3%). No diagnosis was proposed in 22% of the cases. CONCLUSIONS We describe a previously undescribed clinical sign which is characterized by a chronic bilateral erythematous intertrigo located in the perialar region. It can be isolated or associated with various facial dermatoses.
Collapse
Affiliation(s)
- Adrien Sanchez
- Department of Dermatology‐VenereologyHôpital Archet 2, CHU de NiceNiceFrance
| | - Emmanuel Mahe
- Department of Dermatology‐VenereologyCentre Hospitalier d'ArgenteuilArgenteuilFrance
| | - Juliette Miquel
- Pediatric Dermatology UnitHôpital de Saint Pierre, CHU de la RéunionSaint PierreFrance
| | - Claire Abasq
- Department of Dermatology‐VenereologyHôpital Morvan, CHU de BrestBrestFrance
| | - Alice Phan
- Pediatric Dermatology UnitHôpital Femme‐Mère‐Enfant, Hospices Civils de LyonBronFrance
| | | | - Juliette Lemille
- General Medicine, Hôpital Saint‐Jacques, CHU de NantesNantesFrance
| | - Annabel Maruani
- Department of Dermatology, Unit of Paediatric DermatologyUniversity of Tours, CHU de ToursToursFrance
| | | | - Patrice Plantin
- Department of Dermatology‐VenereologyCentre Hospitalier de QuimperQuimperFrance
| | - Stéphanie Mallet
- Department of Dermatology‐VenereologyHôpital de la Timone, Assistance Publique Hôpitaux de MarseilleMarseilleFrance
| | - Hélène Martin
- Department of Dermatology‐VenereologyHôpital Archet 2, CHU de NiceNiceFrance
| | - Thomas Hubiche
- Department of Dermatology‐VenereologyHôpital Archet 2, CHU de NiceNiceFrance
| | | | | | | |
Collapse
|
7
|
Lasek A, Bellon N, Mallet S, Puzenat E, Bursztejn AC, Abasq C, Mazereeuw-Hautier J, Chiaverini C, Hubiche T, Raison Peyron N, Du Thanh A, Barbarot S, Aubert H, Reguiai Z, Droitcourt C, Fievet C, Bellissen A, Bachelerie M, Nosbaum A, Leymarie A, Armingaud P, Masson Regnault M, Mahé E. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicenter retrospective cohort in daily practice. J Eur Acad Dermatol Venereol 2022; 36:2423-2429. [PMID: 35854650 DOI: 10.1111/jdv.18450] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 06/24/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD). OBJECTIVE The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice. METHODS Patients aged 6 to 11, who had received a first dose of dupilumab were included in this multicenter retrospective cohort study. The primary endpoint was change in SCORAD after 3 months of treatment. Secondary endpoints were change in IGA score at 3 months, proportion of patients with SCORAD50 and SCORAD75, description of adverse events and proportion of children in our cohort who would be excluded from pivotal phase 3 clinical trial. RESULTS 80 patients were included. After 3 months of treatment, there was a significant decrease in SCORAD (mean: 21.8 ± 13.8 vs 53.9 ± 18.5; p<0.0001) and IGA (1.3 ± 0.8 vs 3.5 ± 0.7; p<0.0001). Conjunctivitis was observed in 11.3%(n=9/80); 3 patients experienced dupilumab facial redness (DFR); 17.5% (n=14/80) reported injection site reactions; 6.3% (n=5/80) discontinued treatment. 61.2 % (n=49/80) children were ineligible in the phase 3 trial. LIMITATIONS There is no control group. Because it was a real life study based on information from patient medical records in a French multicenter cohort, we cannot rule out the presence of reporting bias generated by the use of patient reported characteristics and missing information. CONCLUSION These real-life data confirm the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo but it also revealed a lower frequency of DFR and conjunctivitis. However, administration in injectable form may be a barrier in this age group.
Collapse
Affiliation(s)
- A Lasek
- Department of dermatology, Hôpital Saint Vincent de Paul, GHICL, Lille, France
| | - N Bellon
- Department of dermatology, Centre Hospitalier Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - S Mallet
- Department of dermatology, venereology, and cancerology, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - E Puzenat
- Department of dermatology, Centre Hospitalier Universitaire deBesançon, Besançon, France
| | - A C Bursztejn
- Department of dermatology, Hôpitaux de Brabois, CHRU Nancy, Vandœuvre-Lès-, Nancy, France
| | - C Abasq
- Department of dermatology, Centre Hospitalier Universitaire de Brest, Brest, France
| | - J Mazereeuw-Hautier
- Department of dermatology, Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier Toulouse, France
| | - C Chiaverini
- Department of dermatology, hospital Archet 2, ESPIC CHU-Lenval, Nice, France
| | - T Hubiche
- Department of dermatology, hospital Archet 2, ESPIC CHU-Lenval, Nice, France
| | - N Raison Peyron
- Department of dermatology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - A Du Thanh
- Department of dermatology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - S Barbarot
- Department of dermatology, Hôtel-Dieu, Nantes, France
| | - H Aubert
- Department of dermatology, Hôtel-Dieu, Nantes, France
| | - Z Reguiai
- Department of dermatology, Polyclinique de Courlancy, Reims, France
| | - C Droitcourt
- Department of dermatology, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France
| | - C Fievet
- Department of dermatology, Centre Hospitalier Régional Universitaire Lille, Lille, France
| | - A Bellissen
- Department of dermatology, Centre Hospitalier d'Aubagne, Aubagne, France
| | - M Bachelerie
- Department of dermatology, Centre Hospitalier Universitaire de Clermond Ferrand, Clermont-Ferrand, France
| | - A Nosbaum
- Department of Clinical Immunology and Allergy, Lyon-Sud University Hospital, Pierre Bénite, Lyon, Lyon, France
| | - A Leymarie
- Department of dermatology, Centre Hospitalier Universitaire de Caen, Caen, France
| | - P Armingaud
- Department of dermatology, Centre Hospitalier d'Orléans, Orléans, France
| | | | - E Mahé
- Department of dermatology, Centre Hospitalier Victor Dupouy, Argenteuil, France
| | | | | |
Collapse
|
8
|
Mahe E, Shourick J, Mallet S, Abasq C, Bursztejn AC, Sampogna F, Bodemer C, Boralevi F, Barbarot S, Lasek A, Merhand S, Taïeb C, Ezzedine K. Perceived clinical severity of atopic dermatitis in children: comparison between patients' and parents' evaluation. J Eur Acad Dermatol Venereol 2022; 36:e592-e594. [PMID: 35293021 DOI: 10.1111/jdv.18083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 02/14/2022] [Accepted: 02/24/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Emmanuel Mahe
- Department of Dermatology, Hôpital Victor Dupouy, 69 rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France
| | - Jason Shourick
- Dermatologist, Epidemiologist, Hôpital de Toulouse, Toulouse, France
| | - Stephanie Mallet
- Service de Dermatologie, Vénéréologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - Claire Abasq
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| | - Anne-Claire Bursztejn
- Service de Dermatologie, CHU de Nancy-Hôpitaux de Brabois, Rue du Morvan, 54500, Vandœuvre-lès-Nancy, France
| | - Francesca Sampogna
- Health Services Research Unit, Istituto Dermopatico dell'Immacolata, Rome, Italy
| | | | - Franck Boralevi
- Pediatric Dermatology Unit, Hospital Pellegrin, University Centre Hospital of Bordeaux, Bordeaux, France
| | - Sébastien Barbarot
- Department of Dermatology, Nantes University Hospital, 44035, Nantes, France
| | - Audrey Lasek
- Service de dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, France
| | | | - Charles Taïeb
- Patients Priority Department, European Market Maintenance Assessment [EMMA], Fontenay Sous Bois, France
| | - Khaled Ezzedine
- Department of Dermatology, Hôpital Henri Mondor, FR-94000, Creteil, France
| |
Collapse
|
9
|
Hazard M, Chinazzo M, Maakaroun‐Vermesse Z, Abasq C, Gaudy‐Graffin C, Tavernier E, Maruani A. Suppressive therapy for recurrent cutaneous herpes infections in children under 12 years: An observational study. Acta Paediatr 2022; 111:138-140. [PMID: 34704300 DOI: 10.1111/apa.16165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Accepted: 10/25/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Margaux Hazard
- Department of Paediatrics University Hospital Center of Tours Tours France
| | - Marie Chinazzo
- Department of Paediatrics University Hospital Center of Tours Tours France
| | | | - Claire Abasq
- Department of Dermatology University Hospital Center of Brest Brest France
| | | | - Elsa Tavernier
- University of ToursINSERM 1246‐SPHERE Tours France
- Clinical Investigation Center of Tours‐INSERM 1415 Tours France
| | - Annabel Maruani
- University of ToursINSERM 1246‐SPHERE Tours France
- Unit of paediatric Dermatology Department of Dermatology University Hospital Center of Tours Tours France
| |
Collapse
|
10
|
Phan C, Beauchet A, Reguiai Z, Severino-Freire M, Mazereeuw-Hautier J, Bursztejn AC, Barbarot S, Hadj-Rabia S, Girard C, Phan A, Lacour JP, Lasek A, Abasq C, Brenaut E, Perrussel M, Droitcourt C, Mallet S, Piram M, Fougerousse AC, Barthélémy H, Balguérie X, Mahé E. Switching biologics in children with psoriasis: Results from the BiPe cohort. Pediatr Dermatol 2022; 39:35-41. [PMID: 34888920 DOI: 10.1111/pde.14845] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 09/28/2021] [Accepted: 10/09/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND There is currently little information on switching biologics in pediatric psoriasis. OBJECTIVE To evaluate the real-world clinical practice and safety of switching biologics in the "Biological Treatments for Pediatric Psoriasis" (BiPe) cohort. METHODS Data for all 134 patients included in the BiPe cohort were analyzed. A further evaluation of the subpopulation of patients who switched from a first-line biologic to a second-line biologic was then conducted. Drug survival rates were also compared between biologics given as first-line or second-line agents. RESULTS Overall, 29 patients (female: 55%; mean age: 16.6 ± 3.0 years) switched between two biologics. Etanercept (ETN) was the first-line biologic used in 23 patients: 16 (69.6%) switched to adalimumab (ADA) and seven (30.4%) to ustekinumab (UST). Six patients received first-line ADA and switched to UST. Loss of efficacy (62.1%), primary inefficacy (20.7%), and parental choice (6.9%) were the main reasons for switching biologics. One (3.4%) of the switches was performed because of adverse events or intolerance. For UST and ADA, the 18-month drug survival rate did not differ according to whether the agent was given as a first-line or second-line biologic (UST: P = .24; ADA: P = .68). No significant differences in drug survival rates were observed between the three different switches (ADA to UST, ETN to ADA, and ETN to UST). CONCLUSION Our study provided key insights into the real-life clinical practice of switching biologics in pediatric psoriasis patients. However, more information and guidance on switching biologics in pediatric psoriasis are needed to improve real-life practice and outcomes.
Collapse
Affiliation(s)
- Céline Phan
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - Alain Beauchet
- Service de Santé Publique, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Ziad Reguiai
- Service de Dermatologie, Polyclinique Courlancy, Hôpital Robert Debré, Reims, France
| | | | | | | | | | - Smaïl Hadj-Rabia
- Service de Dermatologie, INSERM U1163 & Institut Imagine, Centre Hospitalier Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes - Sorbonne, Paris, France
| | - Céline Girard
- Service de Dermatologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Alice Phan
- Service de Pédiatrie, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
| | | | - Audrey Lasek
- Service de Dermatologie, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Claire Abasq
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| | - Emilie Brenaut
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| | - Marc Perrussel
- Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France
| | - Catherine Droitcourt
- Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France
| | - Stéphanie Mallet
- Service de Dermatologie, Vénéréologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - Maryam Piram
- Service de Dermatologie, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin Bicêtre, France
| | | | | | - Xavier Balguérie
- Service de Dermatologie, Centre Hospitalier Universitaire Charles-Nicolle, Rouen, France
| | - Emmanuel Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | | |
Collapse
|
11
|
Boccara O, Mazereeuw J, Martin L, Bessis D, Hubiche T, Chiaverini C, Dompmartin A, Mallet S, Miquel J, Aubert H, Puzenat E, Abasq C, Gusdorf L, Hadj-Rabia S, Maruani A. Central nervous system screening in capillary malformation-arteriovenous malformation syndrome: an observational study. J Am Acad Dermatol 2021; 87:914-916. [PMID: 34954287 DOI: 10.1016/j.jaad.2021.12.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 12/07/2021] [Accepted: 12/15/2021] [Indexed: 11/18/2022]
Affiliation(s)
- Olivia Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France.
| | - Juliette Mazereeuw
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases, Paul Sabatier University Toulouse, Larrey Hospital, Toulouse, France
| | | | - Didier Bessis
- Department of Dermatology, CHU Montpellier, Montpellier, France
| | | | | | | | | | - Juliette Miquel
- Unit of Pediatric Dermatology, CHU Reunion, Saint Pierre, France
| | - Hélène Aubert
- Department of Dermatology, CHU Nantes, Nantes, France
| | - Eve Puzenat
- Department of Dermatology, CHU Besançon, Besançon, France
| | - Claire Abasq
- Department of Dermatology, CHU Brest, Brest, France
| | | | - Smail Hadj-Rabia
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - Annabel Maruani
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Universities of Nantes and Tours, Inserm 1246-SPHERE, CHU Tours, Tours, France
| |
Collapse
|
12
|
Marniquet ME, Seneschal J, Darrigade AS, Staumont-Sallé D, Jachiet M, Nosbaum A, Tauber M, Abasq C, Ferrier Le Bouedec MC, Droitcourt C, Aubert H, Bernier C, Soria A, Raison-Peyron N, Tétart F, Aubin F, Viguier M, Valois A, Kupfer-Bessaguet I, Goronflot T, Barbarot S. Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice. Br J Dermatol 2021; 186:733-735. [PMID: 34748654 DOI: 10.1111/bjd.20883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 11/01/2021] [Accepted: 11/07/2021] [Indexed: 11/28/2022]
Abstract
Dupilumab, an anti-IL-4ɑ monoclonal antibody, has shown a positive benefit-risk ratio when treating moderate to severe atopic dermatitis (AD) in clinical studies (1). High persistence on dupilumab has recently been reported in clinical-practice setting with 77% of patients remaining in treatment for 12 months in a retrospective study including 1,963 patients with AD but reasons for discontinuation were not investigated (2).
Collapse
Affiliation(s)
| | - J Seneschal
- Dermatologie, Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin disorders, Univ. Bordeaux, INSERM, BMGIC, U1035, F-33000, Bordeaux, France
| | - A-S Darrigade
- Dermatologie, Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin disorders, Univ. Bordeaux, INSERM, BMGIC, U1035, F-33000, Bordeaux, France
| | | | - M Jachiet
- Dermatologie, Université de Paris, AP-HP, Service de dermatologie, Hôpital Saint-Louis, F-75010, Paris, France
| | - A Nosbaum
- Dermatologie, Hospices Civils de Lyon, Service d'Allergologie et Immunologie clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - M Tauber
- Dermatologie, CHU de Toulouse, Toulouse, France
| | - C Abasq
- Dermatologie, CHU de Brest, Brest, France
| | | | | | - H Aubert
- Dermatologie, CHU de Nantes, Nantes, France
| | - C Bernier
- Dermatologie, CHU de Nantes, Nantes, France
| | - A Soria
- Sorbonne Université, service de Dermatologie et d'Allergologie, Hôpital Tenon, APHP, Paris, France
| | | | - F Tétart
- Dermatologie, CHU de Rouen, Rouen, France
| | - F Aubin
- Dermatologie, CHU de Besançon, Besançon, France
| | - M Viguier
- Dermatologie, Hôpital Robert Debré, CHU de Reims, Reims, France
| | - A Valois
- Dermatologie, Hôpital d'instruction des Armées Sainte Anne, Toulon, France
| | | | - T Goronflot
- Epidemiologie et Biostatistique, CHU de Nantes, Nantes, France
| | - S Barbarot
- Dermatologie, CHU de Nantes, Nantes, France
| | | |
Collapse
|
13
|
Bursztejn AC, Shourick J, Bodemer C, Lasek A, Mahé E, Merhand S, Sampogna F, Taïeb C, Boralevi F, Ezzedine K, Barbarot S, Mallet S, Abasq C. Feelings of guilt in parents of children with atopic dermatitis. J Eur Acad Dermatol Venereol 2021; 36:e155-e157. [PMID: 34586676 DOI: 10.1111/jdv.17712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 09/17/2021] [Indexed: 11/30/2022]
Affiliation(s)
- A C Bursztejn
- Service de Dermatologie, CHU de Nancy-Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France
| | - J Shourick
- Dermatologist, Epidemiologist, Hôpital de Toulouse, Toulouse, France
| | - C Bodemer
- Department of Dermatology, Hôpital Necker, AP-HP, Paris, France
| | - A Lasek
- Service de dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France
| | - E Mahé
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | - S Merhand
- French Eczema Association, Redon, France
| | - F Sampogna
- Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy
| | - C Taïeb
- Patients Priority Department, European Market Maintenance Assessment [EMMA], Fontenay Sous Bois, France
| | - F Boralevi
- Pediatric Dermatology Unit, Hospital Pellegrin, University Centre Hospital of Bordeaux, Bordeaux, France
| | - K Ezzedine
- Department of Dermatology, Hôpital Henri Mondor, Creteil, France
| | - S Barbarot
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - S Mallet
- Service de Dermatologie, Vénéréologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France
| | - C Abasq
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| |
Collapse
|
14
|
Bedouelle E, Ben Said B, Tetart F, Milpied B, Welfringer-Morin A, Maruani A, Catteau B, Dezoteux F, Staumont-Sallé D, Mazereeuw-Hautier J, Abasq C, Chiaverini C, Delaunay J, Mallet S, Sterling B, Puzenat E, Raynal M, Collet E, Bernier C. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Series of 49 French Pediatric Cases. J Allergy Clin Immunol Pract 2021; 10:267-274.e5. [PMID: 34332174 DOI: 10.1016/j.jaip.2021.07.025] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 06/23/2021] [Accepted: 07/02/2021] [Indexed: 12/17/2022]
Abstract
BACKGROUND Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare and potentially fatal adverse reaction. It can be difficult to diagnose, even more so among children, because symptoms may mimic other commonly encountered pediatric conditions. OBJECTIVE To describe clinical and laboratory features of DRESS syndrome in the pediatric population (age ≤18 years) and establish causative agents and treatment modalities. METHODS This was a multicenter retrospective study of probable and definite DRESS cases (Registry of Sever Cutaneous Adverse Reaction score ≥ 4) in children hospitalized in 15 French university hospitals between 2000 and 2020. RESULTS We included 49 cases. All children had fever and rash, 69.4% had lymphadenopathy, and 65.3% had facial edema. The most common organ affected was the liver (83.7%). Treatment consisted of topical corticosteroid in only 30.6% and systemic corticosteroid in 55.1%; 12.2% received intravenous immunoglobulin. Among probable and likely culprit drugs, 65% were antibiotics and 27.5% were antiepileptics, median time to DRESS symptom onset after initiation of 15 days (13 days with antibiotics and 21 days with antiepileptics). Twenty-seven children had allergy assessment for causative agents, 65.4% of whom had positive tests. CONCLUSIONS Culprit drugs are frequently antibiotics and antiepileptic drugs, and onset is often less than 2 weeks after treatment starts, especially with antibiotics. Treatment with topical corticosteroids appears to be sufficient in the least severe cases. Treatment by systemic corticosteroid therapy remains the reference treatment in case of severe organ damage.
Collapse
Affiliation(s)
- Eve Bedouelle
- Service de Dermatologie, Hôtel Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France.
| | - Benoit Ben Said
- Service de Dermatologie, Centre Hospitalier Universitaire de Lyon, Lyon, France
| | - Florence Tetart
- Service de Dermatologie, Centre Hospitalier Universitaire de Rouen, Rouen, France; Centre Erik Satie, Unité d'Allergologie, Centre Hospitalier Universitaire de Rouen, Rouen, France
| | - Brigitte Milpied
- Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Saint-André et Pellegrin, Bordeaux, France
| | - Anne Welfringer-Morin
- Service de Dermatologie, Centre de Référence des Génodermatoses et des Maladies Rares à Expression Cutanée, Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants Malades Université de Paris, Paris, France
| | - Annabel Maruani
- Université de Tours, INSERM 1246-SPHERE, Service de Dermatologie, Unité de Dermatologie Pédiatrique, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Benoit Catteau
- Service de Dermatologie Center Hospitalier Universitaire de Lille, Université de Lille, Institute for Translational Research in Inflammation, INSERM, Lille, France
| | - Frédéric Dezoteux
- Service de Dermatologie Center Hospitalier Universitaire de Lille, Université de Lille, Institute for Translational Research in Inflammation, INSERM, Lille, France
| | - Delphine Staumont-Sallé
- Service de Dermatologie Center Hospitalier Universitaire de Lille, Université de Lille, Institute for Translational Research in Inflammation, INSERM, Lille, France
| | | | - Claire Abasq
- Service de Dermatologie, Centre Hospitalier Régional Universitaire de Brest, Brest, France
| | | | - Juliette Delaunay
- Service de Dermatologie, Centre Hospitalier Universitaire d'Angers site Larrey, Angers, France
| | - Stéphanie Mallet
- Service de Dermatologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France
| | - Benoit Sterling
- Services de Pédiatrie et Pneumologie Pédiatrique, Hôpital de La Timone-Enfants et Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France
| | - Eve Puzenat
- Service de Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| | - Margot Raynal
- Service de Dermatologie, Centre Hospitalier Universitaire de Rouen, Rouen, France
| | - Evelyne Collet
- Service de Dermatologie, Hôpital Le Bocagen, Centre Hospitalier Régional Universitaire de Dijon, Dijon, France
| | - Claire Bernier
- Service de Dermatologie, Hôtel Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France.
| | | |
Collapse
|
15
|
Barbarot S, Boralevi F, Shourick J, Sampogna F, Mahé E, Merhand S, Bursztejn AC, Mallet S, Ezzedine K, Abasq C, Taïeb C, Lasek A, Bodemer C. Characteristics of children and adolescents with atopic dermatitis who attended therapeutic patient education. J Eur Acad Dermatol Venereol 2021; 35:2263-2269. [PMID: 34273203 DOI: 10.1111/jdv.17526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 06/25/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease. Therapeutic patient education (TPE) has been demonstrated to be effective in AD in reducing disease severity and improving coping and quality of life. OBJECTIVES To describe the sociodemographic and clinical characteristics of children and adolescents with AD who had attended TPE sessions, as well as the characteristics of their parents, and compare them with those who did not attend TPE. METHODS Parents of children with AD aged 6-17 years old were recruited from a representative sample of the French population contacted by e-mail. Sociodemographic data and clinical information were collected in patients and parents. Clinical severity was assessed by parents using a proxy version of the Patient-Oriented Eczema Measure (POEM). Attendance to TPE sessions was assessed by the following question 'did your child or one or both parents attended TPE for AD?'. Also, the number of sessions was recorded. Determinants of TPE attendance were evaluated by univariable and multivariable analyses. RESULTS Data were collected on 1063 parents and children with AD. A total of 131 (12.3%) children and/or parents attended TPE sessions. Most of them attended 2-5 TPE sessions. In that group, there were 85 boys (64.9%), and severity evaluated by POEM was mild in 29.8%, moderate in 52.7% and severe in 17.6% of patients. In the multivariable model, attending TPE sessions was significantly associated with sex of the child (boy vs. girl), consultation with a dermatologist or a paediatrician, high clinical severity and presence of AD in parents. CONCLUSIONS Despite recommendations, the use of TPE in children with AD is still low in France. There is a need for implementing such programmes in the management of the disease, in particular when the disease is severe.
Collapse
Affiliation(s)
- S Barbarot
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - F Boralevi
- Pediatric Dermatology Unit, Hospital Pellegrin, University Centre Hospital of Bordeaux, Bordeaux, France
| | - J Shourick
- Dermatologist, Epidemiologist, Hôpital de Toulouse, Toulouse, France
| | - F Sampogna
- Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy
| | - E Mahé
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | - S Merhand
- French Eczema Association, Association Fraçaise de l'Eczéma, Redon, France
| | - A-C Bursztejn
- Service de Dermatologie, CHU de Nancy-Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France
| | - S Mallet
- Service de Dermatologie, Vénéréologie et Cancérologie Cutanée, Hôpital de la Timone, Assistance-publique, Hôpitaux de Marseille, Marseille, France
| | - K Ezzedine
- Department of Dermatology, Hôpital Henri Mondor, Creteil, France
| | - C Abasq
- Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France
| | - C Taïeb
- Patients Priority Department, European Market Maintenance Assessment [EMMA], Fontenay Sous Bois, France
| | - A Lasek
- Service de Dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France
| | - C Bodemer
- Department of Dermatology, Hôpital Necker, AP-HP, Paris, France
| |
Collapse
|
16
|
Fluhr JW, Gueguen A, Legoupil D, Brenaut E, Abasq C, Araújo H, Misery L. Teledermatology in Times of COVID-19 Confinement: Comparing Patients' and Physicians' Satisfaction by the Standardized Brest Teledermatology Questionnaire. Dermatology 2021; 237:1-6. [PMID: 33567427 PMCID: PMC8018192 DOI: 10.1159/000514029] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Accepted: 12/04/2020] [Indexed: 11/19/2022] Open
Abstract
The French government imposed the first COVID-19 pandemic lockdown from March 17 until May 11, 2020. Only emergency cases and teledermatology (TD) were allowed in outpatient settings. A standardized questionnaire was developed to compare the satisfaction level of patients and their treating physicians. Our main question was whether the patients would perceive TD as a valid alternative for direct physical face-to-face consultation. Eighty-two patients and their 4 treating dermatologists from one dermatology department participated in the study (43 females, 39 males) with a mean age of 46.6 years (SD ±23.9). The reason for TD was a chronic disease in the majority (87.8%), and mainly as a follow-up (96.3%). Regarding satisfaction, almost all categories rated around 9 on a 0-10 verbal analogue scale. The same level of global satisfaction could be seen between the patients and the physicians as well as for the quality of the patient-physician relation and whether all questions could be addressed during the TC. Physicians showed significantly higher scores than patients only for the category of "length" of the consultation. Gender, age, as well as distance between the clinic and home of the patient were not influencing factors for satisfaction. Regarding the technical parameters, the evaluation was mostly comparable for patients and physicians, but overall lower than the relational satisfaction parameters, especially for image quality. Patients were significantly more motivated to continue the TD after the lockdown than their treating dermatologists. We see an interest for implementing TD in specialized centers with chronic patients coming from remote places for regular follow-ups. TD cannot replace in-person patient-physician interaction, but was helpful during the lockdown. As a result, TD might become part of dermatology training to prepare for future lockdown situations.
Collapse
Affiliation(s)
- Joachim W Fluhr
- Univ Brest, LIEN, Brest, France,
- Department of Dermatology, CHRU Brest, Brest, France,
- Department of Dermatology, Charité - Universitätsmedizin, Berlin, Germany,
| | - Annie Gueguen
- Department of Dermatology, CHRU Brest, Brest, France
| | - Delphine Legoupil
- Univ Brest, LIEN, Brest, France
- Department of Dermatology, CHRU Brest, Brest, France
| | - Emilie Brenaut
- Univ Brest, LIEN, Brest, France
- Department of Dermatology, CHRU Brest, Brest, France
| | - Claire Abasq
- Univ Brest, LIEN, Brest, France
- Department of Dermatology, CHRU Brest, Brest, France
| | | | - Laurent Misery
- Univ Brest, LIEN, Brest, France
- Department of Dermatology, CHRU Brest, Brest, France
| |
Collapse
|
17
|
Raynal M, Bellon N, Alby C, Catteau B, Abasq C, Baran R, Steffann J, Bodemer C, Hadj-Rabia S. Variabilité phénotypique du syndrome ichtyose folliculaire, alopécie, photophobie (IFAP). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Flament J, Jouen F, Tancrède-Bohin E, Oro S, Picard-Dahan C, Konstantinou M, Dereure O, Seta V, Quereux G, Prost C, Bedane C, Debarbieux S, Bourgault-Villada I, Delaporte E, Lacour JP, Richard MA, Pham-Ledard A, D’Incan M, Abasq C, Duvert-Lehembre S, Lombart F, Dupuy A, Hainaut E, Dompmartin A, Leccia MT, Vabres P, Alcaraz I, Michel C, Lagrange B, Litrowski N, Estève E, Machet L, Martin L, Del Giudice P, Fenot M, Belmondo T, Morin F, Tressières B, Joly P, Cordel N. Étude du taux d’anticorps anti-BPAG2, mesuré par technique ELISA, comme biomarqueur des complications gravidiques au cours de la pemphigoïde de la grossesse. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Sanchez A, Mahé E, Miquel J, Abasq C, Phan A, Mazereeuw-Hautier J, Lemille J, Maruani A, Bonniaud B, Plantin P, Mallet S, Martin H, Hubiche T, Chiaverini C, Lacour JP. Intertrigo péri-alaire de l’enfant et de l’adolescent : étude descriptive prospective multicentrique d’une nouvelle entité clinique (Étude TRIGONASO). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Masmoudi W, Vaillant M, Vassileva S, Patsatsi A, Quereux G, Moltrasio C, Abasq C, Prost-Squarcioni C, Kottler D, Kiritsi D, Litrowski N, Plantin P, Friedrichsen L, Zebrowska A, Duvert-Lehembre S, Hofmann S, Ferranti V, Jouen F, Joly P, Hebert V. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid. Br J Dermatol 2020; 184:1106-1112. [PMID: 33067805 DOI: 10.1111/bjd.19611] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/15/2020] [Indexed: 11/28/2022]
Abstract
BACKGROUND The Bullous Pemphigoid Disease Area Index (BPDAI) score has been proposed to provide an objective measure of bullous pemphigoid (BP) activity. OBJECTIVES The objective of this study was to calculate BPDAI cut-off values defining mild, moderate and severe BP. We also aimed to assess the interrater reliability and correlation with the number of daily new blisters, and anti-BP180 and anti-BP230 antibodies. METHODS Severity scores were recorded by two blinded investigators. Anti-BP180 and anti-BP230 antibodies were measured using an enzyme-linked immunosorbent assay (ELISA). Cut-off values defining mild, moderate and severe subgroups were calculated based on the 25th and 75th percentiles of the BPDAI score. RESULTS In total, 285 patients with BP were enrolled from 50 dermatology departments in Europe. Median BPDAI activity was 37·5 points (range 0-164). Cut-off values corresponding to the first and third quartiles of the BPDAI score were 20 and 57, respectively; thus, these values were used to define mild (≤ 19), moderate (≥ 20 and ≤ 56) and severe (≥ 57) BP. The median BPDAI score for patients with ≤ 10 daily new blisters was 26 [interquartile range (IQR) 17-45], and for patients with > 10 daily new blisters the median score was 55 (IQR 39-82). The BPDAI intraclass correlation coefficient measured at baseline was 0·97 and remained higher than 0·90 up to month 6. The improvement in the BPDAI score was correlated with the absolute decrease in anti-BP180 ELISA value (Spearman's rank r = 0·34, P < 0·004), but not with anti-BP230 antibodies (r = 0·17, P = 0·15). CONCLUSIONS This study suggests cut-off values of 20-57 for BPDAI to distinguish mild, moderate and severe BP, and confirms that it is a robust tool to assess BP severity precisely.
Collapse
Affiliation(s)
- W Masmoudi
- Department of Dermatology, Centre de Référence des Maladies Bulleuses Autoimmunes
| | - M Vaillant
- Department of Immunology, INSERM U1234, Rouen University Hospital, Rouen, France
| | - S Vassileva
- Department of Dermatology, Medical University of Sofia, Sofia, Bulgaria
| | - A Patsatsi
- 2nd Department of Dermatology and Venerology, Papageorgiou General Hospital, Aristotle University School of Medicine, Thessaloniki, Greece
| | - G Quereux
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - C Moltrasio
- Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - C Abasq
- Department of Dermatology, Brest University Hospital, Brest, France
| | - C Prost-Squarcioni
- Department of Dermatology, Avicenne Hospital, University Paris 13, Bobigny, France
| | - D Kottler
- Department of Dermatology, Bichat Hospital, AP-HP, Paris, France
| | - D Kiritsi
- Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany
| | - N Litrowski
- Department of Dermatology, Monod General Hospital, Le Havre, France
| | - P Plantin
- Department of Dermatology, Centre Hospitalier de Cornouaille, Quimper, France
| | - L Friedrichsen
- Department of Dermatology, University of Lubeck, Lubeck, Germany
| | - A Zebrowska
- Department of Dermatology and Venerology, Medical University of Lodz, Lodz, Poland
| | | | - S Hofmann
- Department of Dermatology, HELIOS University of Wuppertal, Wuppertal, Germany
| | - V Ferranti
- Department of Dermatology, Centre de Référence des Maladies Bulleuses Autoimmunes
| | - F Jouen
- Department of Dermatology, Centre de Référence des Maladies Bulleuses Autoimmunes.,Department of Immunology, INSERM U1234, Rouen University Hospital, Rouen, France
| | - P Joly
- Department of Dermatology, Centre de Référence des Maladies Bulleuses Autoimmunes.,Department of Immunology, INSERM U1234, Rouen University Hospital, Rouen, France
| | - V Hebert
- Department of Dermatology, Centre de Référence des Maladies Bulleuses Autoimmunes.,Department of Immunology, INSERM U1234, Rouen University Hospital, Rouen, France
| | | |
Collapse
|
21
|
Chambrelan E, Barbarot S, Bekel L, Poizeau F, Mahé E, Puzenat E, Delaunay J, Mallet S, Bessis D, Maruani A, Miquel J, Raison-Peyron N, Abasq C, Phan A, Du Thanh A, Kupfer I, Bonniaud B, Bouzille G, Dupuy A, Droitcourt C. Drug survival and postdrug survival of systemic treatments in a national French cohort of children with atopic dermatitis. Br J Dermatol 2020; 183:376-378. [PMID: 32037515 DOI: 10.1111/bjd.18941] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- E Chambrelan
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes 1, F35000, Rennes, France
| | - S Barbarot
- Department of Dermatology, CHU Nantes, F44093, Nantes, France
| | - L Bekel
- Department of Dermatology and Pediatric Dermatology, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris (APHP), F75015, Paris, France
| | - F Poizeau
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes 1, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - A Dupuy
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes 1, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France
| | - C Droitcourt
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes 1, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France
| | | |
Collapse
|
22
|
Bastos S, Hebert V, Vassileva S, Patsatsi A, Meijer J, Quéreux G, Bedane C, Prost-Squarcioni C, Debardieux S, Oro S, Chaby G, D’Incan M, Litrowski N, Boulard C, Lunardon L, Kiritsi D, Jedlickova H, Feliciani C, Roussel A, Kottler D, Plantin P, Richard MA, Friedrichsen L, Abasq C, Duvert Lehembre S, Gottlieb J, Zebrowska A, Hofmann S, Joly P. Efficacité et tolérance de la prednisone à 0,5 mg/kg/j en traitement initial de la pemphigoïde bulleuse. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Mazaud C, Staumont D, Beauchet A, Catteau B, Lasek A, Puzenat E, Aubin F, Barbarot S, Aubert H, Mallet S, Seneschal J, Bessis D, Tauber M, Delaunay J, Droitcourt C, Abasq C, Jachiet M, Nosbaum A, Mahé E. Dupilumab dans la dermatite atopique modérée à sévère de l’enfant. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Briand C, Gourier G, Poizeau F, Jelti L, Bachelerie M, Quéreux G, Jeudy G, Acquitter M, Oro S, Caux F, Darrigade A, Heron Mermin D, Mahé E, Picart Dahan C, Richard MA, Clerc C, Salle De Chou C, Bernard P, Abasq C, Misery L, Brenaut E. Caractéristiques du prurit dans la pemphigoïde bulleuse et impact sur la qualité de vie: l’étude prospective multicentrique PruriPB. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Phan C, Beauchet A, Burztejn A, Severino‐Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj‐Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour J, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse A, Kupfer‐Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles‐Tsimaratos N, Mery‐Brossard L, Pallure V, Lons‐Danic D, Bouilly‐Auvray D, Beylot‐Barry M, Puzenat E, Aubin F, Mahé E. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol 2019; 33:1984-1992. [DOI: 10.1111/jdv.15579] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 02/27/2019] [Indexed: 02/06/2023]
|
26
|
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. J Invest Dermatol 2019; 139:31-37. [DOI: 10.1016/j.jid.2018.04.042] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 04/20/2018] [Accepted: 04/25/2018] [Indexed: 11/29/2022]
|
27
|
Masmoudi W, Hebert V, Quéreux G, Bedane C, Prost-Squarcioni C, Debarbieux S, Oro S, Chaby G, D’incan M, Litrowski N, Boulard C, Roussel A, Kottler D, Abasq C, Richard MA, Duvert-Lehembre S, Gottlieb J, Plantin P, Joly P. Calcul des valeurs seuils du score BPDAI (Bullous Pemphigoid Disease Area Index) définissant les formes légères, modérées et sévères de la pemphigoïde bulleuse. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Kechichian E, Ingen-Housz-Oro S, Sbidian E, Hemery F, Bernier C, Fite C, Delaunay J, Staumont-Sallé D, Toukal F, Dupin N, Abasq C, Samimi M, Picard C, Hebert V, Prost C, Monfort JB, Milpied B, Wolkenstein P, Chosidow O. A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices. Br J Dermatol 2018; 179:1009-1011. [DOI: 10.1111/bjd.16928] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- E. Kechichian
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
| | - S. Ingen-Housz-Oro
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
- Department of Dermatology; EA 7379 - EpiDermE, Université Paris Est; Créteil France
| | - E. Sbidian
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
- Department of Dermatology; EA 7379 - EpiDermE, Université Paris Est; Créteil France
- Department of Dermatology; Université Paris Est UPEC; Créteil France
| | - F. Hemery
- Department of Medical Information; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
| | - C. Bernier
- Department of Dermatology; CHU Nantes; Nantes France
| | - C. Fite
- Department of Dermatology; APHP, Hôpital Bichat; Paris France
| | - J. Delaunay
- Department of Dermatology; CHU Angers; Angers France
| | - D. Staumont-Sallé
- Department of Dermatology; Hôpital Claude Huriez - CHRU Lille; Lille France
| | - F. Toukal
- Department of Dermatology; Hôpital Saint André Bordeaux; Bordeaux France
| | - N. Dupin
- Department of Dermatology; APHP, Hôpital Tarnier; Paris France
| | - C. Abasq
- Department of Dermatology; Department of Dermatology; CHU Brest; Brest France
| | - M. Samimi
- Department of Dermatology; CHU de Tours; Tours France
| | - C. Picard
- Department of Dermatology; CHU de Caen; Caen France
| | - V. Hebert
- Department of Dermatology; CHU de Rouen; Rouen France
| | - C. Prost
- Department of Dermatology; APHP, Hôpital Avicenne; Bobigny France
| | - J.-B. Monfort
- Department of Dermatology; APHP, Hôpital Tenon; Paris France
| | - B. Milpied
- Department of Dermatology; Hôpital Saint André Bordeaux; Bordeaux France
| | - P. Wolkenstein
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
- Department of Dermatology; EA 7379 - EpiDermE, Université Paris Est; Créteil France
- Department of Dermatology; Université Paris Est UPEC; Créteil France
| | - O. Chosidow
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
- Department of Dermatology; EA 7379 - EpiDermE, Université Paris Est; Créteil France
- Department of Dermatology; Université Paris Est UPEC; Créteil France
| |
Collapse
|
29
|
Maridet C, Perromat M, Miquel J, Chiaverini C, Bessis D, Lasek A, Piram M, Bursztejn AC, Abasq C, Phan A, Martin L, Bréchat B, Chong JH, Seneschal J, Taïeb A, Boralevi F. Childhood chronic prurigo: Interest in patch tests and delayed-reading skin prick tests to environmental allergens. J Allergy Clin Immunol 2018; 141:797-799.e9. [DOI: 10.1016/j.jaci.2017.07.049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Revised: 07/20/2017] [Accepted: 07/31/2017] [Indexed: 11/26/2022]
|
30
|
Lavenant P, Roue JM, Huet F, Abasq C, Misery L, Rioualen S. [DRESS syndrome and agranulocytosis, a rare combination]. Arch Pediatr 2017; 24:752-756. [PMID: 28669649 DOI: 10.1016/j.arcped.2017.05.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2016] [Revised: 02/22/2017] [Accepted: 05/22/2017] [Indexed: 12/17/2022]
Abstract
INTRODUCTION Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe toxidermia that can lead to death from multivisceral failure. We report a case of DRESS associated with febrile agranulocytosis in a child. OBSERVATION An 8-year-old child was hospitalized for diffuse maculopapular exanthema with edema of the extremities and face associated with cheilitis and febrile agranulocytosis. This symptomatology began 1month after the introduction of carbamazepine for partial epilepsy. The clinical picture was a multisystemic disease with colitis, interstitial pneumonitis, hepatic cytolysis, and hepatocellular insufficiency. HHV7 viral reactivation and increased eosinophils (20%) in the myelogram were demonstrated, providing the diagnosis of DRESS. The progression was favorable after carbamazepine therapy was stopped and systemic corticosteroids were administered. DISCUSSION DRESS syndrome is a disorder that is unfamiliar to pediatricians. Its association with agranulocytosis is rare and the absence of hypereosinophilia contributed to diagnostic difficulties in this case. The multisystemic failure, the reactivation of HHV7, the increase of eosinophils in the myelogram, and the favorable progression under systemic corticosteroid therapy contributed greatly to the diagnosis. A cutaneous biopsy was not considered necessary for the diagnosis in the case reported herein. CONCLUSION DRESS syndrome is rarely associated with agranulocytosis, but its diagnosis must be quickly raised so that the incriminated drug can be interrupted.
Collapse
Affiliation(s)
- P Lavenant
- Pôle de la femme, de la mère et de l'enfant, centre hospitalier universitaire, 2, avenue Foch, 29609 Brest, France
| | - J-M Roue
- Pôle de la femme, de la mère et de l'enfant, centre hospitalier universitaire, 2, avenue Foch, 29609 Brest, France; EA4685 (laboratoire de neurosciences de Brest), faculté de médecine et des sciences de la santé, université de Bretagne occidentale, 22, rue Camille-Desmoulins, 29200 Brest, France
| | - F Huet
- Service de dermatologie, centre hospitalier universitaire, 2, avenue Foch, 29609 Brest, France
| | - C Abasq
- Service de dermatologie, centre hospitalier universitaire, 2, avenue Foch, 29609 Brest, France
| | - L Misery
- EA4685 (laboratoire de neurosciences de Brest), faculté de médecine et des sciences de la santé, université de Bretagne occidentale, 22, rue Camille-Desmoulins, 29200 Brest, France; Service de dermatologie, centre hospitalier universitaire, 2, avenue Foch, 29609 Brest, France
| | - S Rioualen
- Pôle de la femme, de la mère et de l'enfant, centre hospitalier universitaire, 2, avenue Foch, 29609 Brest, France; EA4685 (laboratoire de neurosciences de Brest), faculté de médecine et des sciences de la santé, université de Bretagne occidentale, 22, rue Camille-Desmoulins, 29200 Brest, France.
| |
Collapse
|
31
|
Brun J, Chiaverini C, Devos C, Leclerc-Mercier S, Mazereeuw J, Bourrat E, Maruani A, Mallet S, Abasq C, Phan A, Vabres P, Martin L, Bodemer C, Lagrange S, Lacour JP. Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex. Orphanet J Rare Dis 2017; 12:119. [PMID: 28659151 PMCID: PMC5490235 DOI: 10.1186/s13023-017-0666-5] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 06/12/2017] [Indexed: 12/02/2022] Open
Abstract
Background A localized form of epidermolysis bullosa simplex (EBS-l) is considered one of the mildest forms of epidermolysis bullosa (EB), with blisters limited to the palms and soles. However, these lesions can be very painful. The aim of the study was to characterize pain in patients with EBS-l and evaluate its impact on quality of life (QoL). Patients were contacted via the Research Group of the French Society of Pediatric Dermatology and the association of EB patients (DEBRA France). One investigator used a standardized questionnaire that included validated scales for pain and QoL for a telephone interview. Results We included 57 patients (27 children). All patients had pain: the mean pain on a 10-mm visual analog scale was >5 for most adults (90%) and children ≥8 years old (94%) when blisters were present and for most adults (73%) and about half of the children ≥ age 8 (53%) during dressing changes. Similar results were found for younger patients. Overall, 75% of patients had neuropathic pain; for 55% of children and 73% of adults, the pain had a moderate to severe impact on QOL. Only seven patients used premedication before changing dressings and seven regularly used oral treatment for chronic pain. A total of 21% and 23% of patients used non-steroidal anti-inflammatory drugs and grade 2 analgesics, respectively. These treatments were not effective for neuropathic pain. Six patients tried 5% lidocaine plasters on their feet, with good efficacy. Conclusions EBS-l patients have frequent and severe pain with neuropathic characteristics. This pain is undertreated and affects QoL.
Collapse
Affiliation(s)
- Jennifer Brun
- Reference Centre for Inherited Epidermolysis Bullosa, Archet 2 Hospital, University of Nice Sophia Antipolis, Nice, France.
| | - Christine Chiaverini
- Reference Centre for Inherited Epidermolysis Bullosa, Archet 2 Hospital, University of Nice Sophia Antipolis, Nice, France.,INSERM, U1081, CNRS, UMR7284, Institute for Research on Cancer and Aging, Nice (IRCAN), University of Nice Sophia Antipolis, Medical School, Nice, France
| | - Caroline Devos
- Department of Algology, Archet 2 Hospital, University of Nice Sophia Antipolis, Nice, France
| | - Stéphanie Leclerc-Mercier
- Reference Centre for Cutaneous Rare Diseases (MAGEC), Necker Enfants Malades Hospital, University Paris Descartes, Institut Imagine, APHP, Paris, France
| | - Juliette Mazereeuw
- Reference Centre of Rare Diseases of the Skin, Larrey Hospital, Toulouse, France
| | - Emmanuelle Bourrat
- Reference Centre for Cutaneous Rare Diseases (MAGEC), Saint-Louis Hospital, Paris, France
| | | | | | - Claire Abasq
- Department of Dermatology, CHRU de Brest, Brest, France
| | - Alice Phan
- Department of Dermatology, Claude Bernard-Lyon 1 University and Hospices Civils de Lyon, Lyon, France
| | - Pierre Vabres
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Ludovic Martin
- Department of Dermatology, Angers University Hospital, Angers, France
| | - Christine Bodemer
- Reference Centre for Cutaneous Rare Diseases (MAGEC), Necker Enfants Malades Hospital, University Paris Descartes, Institut Imagine, APHP, Paris, France
| | - Sylvie Lagrange
- Reference Centre for Inherited Epidermolysis Bullosa, Archet 2 Hospital, University of Nice Sophia Antipolis, Nice, France
| | - Jean-Philippe Lacour
- Reference Centre for Inherited Epidermolysis Bullosa, Archet 2 Hospital, University of Nice Sophia Antipolis, Nice, France.,INSERM, U1081, CNRS, UMR7284, Institute for Research on Cancer and Aging, Nice (IRCAN), University of Nice Sophia Antipolis, Medical School, Nice, France
| | | |
Collapse
|
32
|
Sobocinski V, Dridi SM, Bisson C, Jeanne S, Gaultier F, Prost-Squarcioni C, Bernard P, Pascal F, Lefevre B, Weber P, Abasq C, Agbo-Godeau S, Joly P, Ingen-Housz-Oro S, Duvert-Lehembre S. [Oral care recommendations for patients with oral autoimmune bullous diseases]. Ann Dermatol Venereol 2016; 144:182-190. [PMID: 28011091 DOI: 10.1016/j.annder.2016.09.680] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Revised: 08/14/2016] [Accepted: 09/23/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND Autoimmune bullous diseases (AIBD) may cause chronic oral lesions that progress insidiously. AIMS To provide recommendations for optimal oral-dental management of patients presenting AIBD with oral involvement. PATIENTS AND METHODS In the absence of scientific studies with high levels of proof, these recommendations have been drawn up at two meetings by a committee of experts on AIBD comprising 7 dermatologists, 1 stomatologist, 1 maxillofacial surgeon, 2 odontologists and 4 parodontologists. RESULTS The oral lesions associated with AIBD may be classified into three grades of severity: severe (generalised erosive gingivitis affecting at least 30% of dental sites), moderate (localised erosive gingivitis affecting less than 30% of dental sites) and controlled (no erosive oral lesions). Good oral-dental hygiene suited to the severity of the oral lesions, must be practised continually by these patients so as to avoid the formation of dental plaque, which aggravates symptoms. Dental and parodontal care must be considered in accordance with the severity grade of the oral lesions: in severe cases, the dental plaque must be eliminated manually with a curette, but several types of care (descaling, treatment for tooth decay, non-urgent extractions, etc.) must be suspended until the grade of severity is moderate or until the disease is stabilised.
Collapse
Affiliation(s)
- V Sobocinski
- Clinique dermatologique, hôpital Charles-Nicolle, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
| | - S-M Dridi
- Service d'odontologie, hôpital Henri-Mondor, 51, avenue du maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - C Bisson
- Service d'odontologie, CHRU de Nancy, 29, avenue de Lattre-de-Tassigny, 54000 Nancy, France
| | - S Jeanne
- Service d'odontologie, CHRU de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France
| | - F Gaultier
- Service d'odontologie, hôpital Henri-Mondor, 51, avenue du maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - C Prost-Squarcioni
- Service de dermatologie, hôpital Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, rue du général-Koening, 51100 Reims, France
| | - F Pascal
- Service de dermatologie, hôpital Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France
| | - B Lefevre
- Service d'odontologie, hôpital Robert-Debré, rue du général-Koening, 51100 Reims, France
| | - P Weber
- Service de dermatologie, hôpital Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France
| | - C Abasq
- Service de dermatologie, hôpital Morvan, 2, avenue maréchal-Foch, 29200 Brest, France
| | - S Agbo-Godeau
- Service de stomatologie et chirurgie maxillo-faciale, hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013 Paris, France
| | - P Joly
- Clinique dermatologique, hôpital Charles-Nicolle, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, 51, avenue du maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - S Duvert-Lehembre
- Service de dermatologie, hôpital de Dunkerque, 130, avenue Louis-Herbeaux, 59240 Dunkerque, France
| |
Collapse
|
33
|
Cordel N, Bessis D, Bourrat E, Maruani A, Chiaverini C, Abasq C, Aubert H, Balguerie X, Oro S, Mahé E, Martin L, Mazereeuw-Hautier J, Phan A, Barbarot S, Vabres P, Jouen F, Tressières B, Boralévi F. Dermatose à IgA linéaire de l’enfant : étude rétrospective multicentrique de 32 cas. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Bessis D, Bigorre M, Malissen N, Captier G, Chiaverini C, Abasq C, Barbarot S, Boccara O, Bourrat E, El Fertit H, Eschard C, Hubiche T, Lacour JP, Leboucq N, Mahé E, Mallet S, Marque M, Martin L, Mazereeuw-Hautier J, Milla N, Phan A, Plantin P, Picot MC, Puzenat E, Rigau V, Vabres P, Fraitag S, Boralevi F. The scalp hair collar and tuft signs: A retrospective multicenter study of 78 patients with a systematic review of the literature. J Am Acad Dermatol 2016; 76:478-487. [PMID: 27742172 DOI: 10.1016/j.jaad.2016.08.046] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 07/27/2016] [Accepted: 08/21/2016] [Indexed: 10/20/2022]
Abstract
BACKGROUND Hair collar sign (HCS) and hair tuft of the scalp (HTS) are cutaneous signs of an underlying neuroectodermal defect, but most available data are based on case reports. OBJECTIVE We sought to define the clinical spectrum of HCS and HTS, clarify the risk for underlying neurovascular anomalies, and provide imaging recommendations. METHODS A 10-year multicenter retrospective and prospective analysis of clinical, radiologic, and histopathologic features of HCS and HTS in pediatric patients was performed. RESULTS Of the 78 patients included in the study, 56 underwent cranial and brain imaging. Twenty-three of the 56 patients (41%) had abnormal findings, including the following: (1) cranial/bone defect (30.4%), with direct communication with the central nervous system in 28.6%; (2) venous malformations (25%); or (3) central nervous system abnormalities (12.5%). Meningeal heterotopia in 34.6% (9/26) was the most common neuroectodermal association. Sinus pericranii, paraganglioma, and combined nevus were also identified. LIMITATIONS The partial retrospective design and predominant recruitment from the dermatology department are limitations of this study. CONCLUSIONS Infants with HCS or HTS are at high risk for underlying neurovascular anomalies. Magnetic resonance imaging scans should be performed in order to refer the infant to the appropriate specialist for management.
Collapse
Affiliation(s)
- Didier Bessis
- Department of Dermatology, Saint-Eloi Hospital, Montpellier, France; Montpellier University Hospital and Institut National de la Santé et de la Recherche Médicale (INSERM) U1058, Montpellier, France.
| | - Michèle Bigorre
- Department of Infantile Plastic Surgery, Lapeyronie Hospital, Montpellier, France
| | | | - Guillaume Captier
- Department of Infantile Plastic Surgery, Lapeyronie Hospital, Montpellier, France
| | | | - Claire Abasq
- Department of Dermatology, Brest University Hospital, Brest, France
| | | | - Olivia Boccara
- Department of Pediatric Dermatology, Necker-Enfants Malades Hospital, Paris, France
| | - Emmanuelle Bourrat
- Department of Pediatric Dermatology, Robert-Debré Hospital, Paris, France
| | - Hassan El Fertit
- Department of Infantile Neurosurgery, Caremeau Hospital, Nîmes, France
| | | | - Thomas Hubiche
- Department of Dermatology and Infectious Diseases, Fréjus Hospital, Fréjus, France
| | | | - Nicolas Leboucq
- Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier, France
| | - Emmanuel Mahé
- Department of Dermatology, Argenteuil Hospital, Argenteuil, France
| | | | - Myriam Marque
- Department of Dermatology, Caremeau Hospital, Nîmes, France
| | - Ludovic Martin
- Department of Dermatology, Angers University Hospital, Angers, France
| | | | - Nathalie Milla
- Department of Dermatology, Saint-Eloi Hospital, Montpellier, France
| | - Alice Phan
- Department of Pediatric Dermatology, Femme-Mère-Enfant Hospital and Claude-Bernard Lyon 1 University, Lyonm, France
| | - Patrice Plantin
- Department of Dermatology, Quimper Hospital, Quimper, France
| | - Marie-Christine Picot
- Unit of Clinical Research and Epidemiology, Department of Medical Information, Antonin Balmes Hospital, Montpellier, France
| | - Eve Puzenat
- Department of Dermatology, Besançon University Hospital, Besançon, France
| | - Valérie Rigau
- Department of Pathology, Montpellier University Hospital, Montpellier, France
| | - Pierre Vabres
- Department of Dermatology, Bocage Hospital and Bourgogne Medical University, Dijon, France
| | - Sylvie Fraitag
- Department of Pathology, Necker-Enfants Malades University Hospital, Paris, France
| | - Franck Boralevi
- Department of Pediatric Dermatology, National Center for Rare Skin Disorders-Institut National de la Santé et de la Recherche Médicale (INSERM) U1035, Bordeaux, France
| | | |
Collapse
|
35
|
Boulard C, Duvert Lehembre S, Picard‐Dahan C, Kern J, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost‐Squarcioni C, Labeille B, Richard M, Ingen‐Housz‐Oro S, Houivet E, Werth V, Murrell D, Hertl M, Benichou J, Joly P, Hofmann S, Camaioni B, Didona B, Fania L, Della Torre R, Caux F, Alexandre M, Paul C, Bulai Livideanu C, Delaporte E, Dupuy A, Avenel‐Audran M, Schmidt E, Schumacher N, Bagot M, Tancrede‐Bohin E, Bouaziz J, D'Incan M, Quereux G, Skowron F, Beylot‐Barry M, Doutre M, Bedane C, Bernard P, Machet L, Jullien ., Debarbieux S, Dereure O, Hünefeld C, Schanz S, Franck N, Maillard H, Misery L, Sassolas B, Abasq C, Bouyeure A, Lagoutte P, Ferranti V. Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (
ABSIS
) and Pemphigus Disease Area Index (
PDAI
) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 2016; 175:142-9. [DOI: 10.1111/bjd.14405] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2016] [Indexed: 11/27/2022]
Affiliation(s)
- C. Boulard
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - S. Duvert Lehembre
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - C. Picard‐Dahan
- Department of Dermatology Bichat University Hospital AP‐HP Paris France
| | - J.S. Kern
- Department of Dermatology Medical Center University of Freiburg Freiburg Germany
| | - G. Zambruno
- Laboratory of Molecular and Cell Biology Istituto Dermopatico dell'Immacolata IRCCS Via Monti di Creta 104 00167 Roma Italy
| | - C. Feliciani
- Policlinico Gemelli – Università Cattolica del ‘Sacro Cuore’ Largo Gemelli 8 00168 Roma Italy
| | - B. Marinovic
- University Hospital Center Zagreb Department of Dermatology and Venereology Salata 4 10000 Zagreb Croatia
| | - P. Vabres
- Department of Dermatology Dijon University Hospital Dijon France
| | - L. Borradori
- Department of Dermatology Universitätsklinik für Dermatologie Inselspital CH‐3010 Bern Switzerland
| | - C. Prost‐Squarcioni
- Department of Dermatology Avicenne Hospital University Paris 13 Bobigny France
| | - B. Labeille
- Department of Dermatology Saint Etienne University Hospital Saint Etienne France
| | - M.A. Richard
- Aix‐Marseille University UMR 911 INSERM CRO2 ‘Centre de Recherche en Oncologie Biologique et Oncophamacologie’ Department of Dermatology Hôpital Timone Assistance Publique des Hôpitaux de Marseille 264 Rue Saint Pierre 13385 Marseille France
| | - S. Ingen‐Housz‐Oro
- Department of Dermatology Henri Mondor University Hospital AP‐HP Créteil France
| | - E. Houivet
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - V.P. Werth
- Department of Dermatology University of Pennsylvania, and Philadelphia VAMC Philadelphia PA U.S.A
| | - D.F. Murrell
- Department of Dermatology St George Hospital University of NSW Sydney Australia
| | - M. Hertl
- Department of Dermatology Philipps University Marburg Marburg Germany
| | - J. Benichou
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - P. Joly
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Charbit L, Mahé E, Phan A, Chiaverini C, Boralevi F, Bourrat E, Lasek A, Maruani A, Aubin F, Droitcourt C, Barbarot S, Mallet S, Mazereeuw-Hautier J, Begon E, Abasq C, Plantin P, Souillet AL, Hadj-Rabia S, Bursztejn AC. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol 2016; 174:1118-21. [DOI: 10.1111/bjd.14326] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- L. Charbit
- Department of Dermatology; Centre Hospitalier Universitaire de Nancy; Nancy France
| | - E. Mahé
- Department of Dermatology; Hôpital Victor Dupouy; Argenteuil France
| | - A. Phan
- Pediatric Dermatology Unit; Claude Bernard - Lyon 1 University; Hôpital Femme-Mère-Enfant; Bron France
| | - C. Chiaverini
- Department of Dermatology; Centre Hospitalier Universitaire de Nice Hôpital l'Archet; Nice France
| | - F. Boralevi
- Pediatric Dermatology Unit; Pellegrin Hospital; Bordeaux France
| | - E. Bourrat
- Department of Pediatrics; Assistance Publique Hôpitaux de Paris Hôpital Saint Louis; Paris France
| | - A. Lasek
- Department of Dermatology; Groupe Hospitalier de l'Institut Catholique de Lille; Lille France
| | - A. Maruani
- Department of Dermatology; Centre Hospitalier Régional Universitaire de Tours Hôpital Trousseau et Université François Rabelais Tours; Tours France
| | - F. Aubin
- Department of Dermatology; Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz; Besançon France
| | - C. Droitcourt
- Department of Dermatology; Centre Hospitalier Universitaire de Rennes; Rennes France
| | - S. Barbarot
- Department of Dermatology; Centre Hospitalier Universitaire de Nantes Hôtel-Dieu; Nantes France
| | - S. Mallet
- Department of Dermatology; Assistance Publique Hôpitaux de Marseille Hôpital de la Timone; Marseille France
| | - J. Mazereeuw-Hautier
- Department of Dermatology; Centre Hospitalier Universitaire de Toulouse Hôpital Larrey; Toulouse France
| | - E. Begon
- Department of Dermatology; Centre Hospitalier René Dubos; Pontoise France
| | - C. Abasq
- Department of Dermatology; Centre Hospitalier Régional Universitaire de Brest; Brest France
| | - P. Plantin
- Department of Dermatology; Centre Hospitalier de Cornouaille Hôpital Laënnec; Quimper France
| | - A.-L. Souillet
- Departement of Pneumology-Allergology-Dermatology; Hôpital Femme-Mère-Enfant; Bron France
| | - S. Hadj-Rabia
- Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC); Department of Dermatology; Université Paris Descartes - Sorbonne Paris Cité; Institut Imagine; Hôpital Universitaire Necker-Enfants Malades; Assistance Publique Hôpitaux de Paris; Paris France
| | - A.-C. Bursztejn
- Department of Dermatology; Centre Hospitalier Universitaire de Nancy; Nancy France
| | | |
Collapse
|
37
|
Marmottant E, Chiaverini C, Bessis D, Hubiche T, Mallet S, Maruani A, Abasq C, Miquel J, Cardot-Leccia N, Lacour JP, Passeron T. Pigmented macules of bony prominences (PMBP): A distinct presentation in patients with red hair. J Am Acad Dermatol 2016; 74:383-5. [PMID: 26775783 DOI: 10.1016/j.jaad.2015.08.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Revised: 08/11/2015] [Accepted: 08/12/2015] [Indexed: 10/22/2022]
Affiliation(s)
| | | | - Didier Bessis
- Department of Dermatology, Hôpital Saint Eloi, Montpellier
| | | | | | | | | | | | | | | | - Thierry Passeron
- Department of Dermatology, Hôpital L'Archet 2, Nice; Department of Pathology, INSERM U1065 Team 12, C3M, Nice.
| |
Collapse
|
38
|
Huet F, Karam A, Lemasson G, Abasq C, Misery L. Érythrodermie révélatrice d’une pemphigoïde bulleuse. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Reproductibilité inter-observateur des scores de sévérité du pemphigus ABSIS et PDAI. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
40
|
Houivet E, Hebert V, Boulard C, Vaillant M, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Corrélation entre les scores de sévérité clinique (ABSIS, PDAI, PGA), la qualité de vie (DLQI) et les taux d’Ac anti-desmogléine 1 et 3 dans le suivi du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
41
|
Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, Godmer P, Abasq C, Astudillo L, Belenotti P, Bessis D, Bigot A, Doutre MS, Ebbo M, Guichard I, Hachulla E, Héron E, Jeudy G, Jourde-Chiche N, Jullien D, Lavigne C, Machet L, Macher MA, Martel C, Melboucy-Belkhir S, Morice C, Petit A, Simorre B, Zenone T, Bouillet L, Bagot M, Frémeaux-Bacchi V, Guillevin L, Mouthon L, Dupin N, Aractingi S, Terrier B. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol 2015; 67:527-34. [PMID: 25385679 DOI: 10.1002/art.38956] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 11/06/2014] [Indexed: 11/10/2022]
Abstract
OBJECTIVE Hypocomplementemic urticarial vasculitis (HUV) is an uncommon vasculitis of unknown etiology that is rarely described in the literature. We undertook this study to analyze the clinical spectrum and the therapeutic management of patients with HUV. METHODS We conducted a French nationwide retrospective study that included 57 patients with chronic urticaria, histologic leukocytoclastic vasculitis, and hypocomplementemia. We assessed clinical and laboratory data and evaluated the patients' cutaneous and immunologic responses to therapy. We evaluated treatment efficacy by measuring the time to treatment failure. RESULTS Urticarial lesions were typically more pruritic than painful and were associated with angioedema in 51% of patients, purpura in 35%, and livedo reticularis in 14%. Extracutaneous manifestations included constitutional symptoms (in 56% of patients) as well as musculoskeletal involvement (in 82%), ocular involvement (in 56%), pulmonary involvement (in 19%), gastrointestinal involvement (in 18%), and kidney involvement (in 14%). Patients with HUV typically presented with low C1q levels and normal C1 inhibitor levels, in association with anti-C1q antibodies in 55% of patients. Hydroxychloroquine or colchicine seemed to be as effective as corticosteroids as first-line therapy. In patients with relapsing and/or refractory disease, rates of cutaneous and immunologic response to therapy seemed to be higher with conventional immunosuppressive agents, in particular, azathioprine, mycophenolate mofetil, or cyclophosphamide, while a rituximab-based regimen tended to have higher efficacy. Finally, a cutaneous response to therapy was strongly associated with an immunologic response to therapy. CONCLUSION HUV represents an uncommon systemic and relapsing vasculitis with various manifestations, mainly, musculoskeletal and ocular involvement associated with anti-C1q antibodies, which were found in approximately half of the patients. The best strategy for treating HUV has yet to be defined.
Collapse
Affiliation(s)
- Marie Jachiet
- Hôpital Cochin, AP-HP, and Université Paris Descartes, Paris 5, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Chatillon JF, Hamieh M, Bayeux F, Abasq C, Fauquembergue E, Drouet A, Guisier F, Latouche JB, Musette P. Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies. Immun Inflamm Dis 2015; 3:1-13. [PMID: 25866635 PMCID: PMC4386909 DOI: 10.1002/iid3.43] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/22/2014] [Revised: 08/25/2014] [Accepted: 09/13/2014] [Indexed: 11/14/2022]
Abstract
Adoptive transfer of in vitro activated and expanded antigen-specific cytotoxic T lymphocytes (CTLs) is a promising therapeutic strategy for infectious diseases and cancers. Obtaining in vitro a sufficient amount of highly specific cytotoxic cells and capable of retaining cytotoxic activity in vivo remains problematic. We studied the role of Toll-Like Receptor-8 (TLR8) engagement on peripheral CTLs activated with melanoma antigen MART-1-expressing artificial antigen-presenting cells (AAPCs). After a 3-week co-culture, 3–27% of specific CTLs were consistently obtained. CTLs expressed TLR8 in the intracellular compartment and at the cell surface. Specific CTLs activated with a TLR8 agonist (CL075) 24 h before the end of the culture displayed neither any change in their production levels of molecules involved in cytotoxicity (IFN-γ, Granzyme B, and TNF-α) nor major significant change in their cell surface phenotype. However, these TLR8-stimulated lymphocytes displayed increased cytotoxic activity against specific peptide-pulsed target cells related to an increase in specific anti-melanoma CTL functional avidity. TLR8 engagement on CTLs could, therefore, be useful in different immunotherapy strategies.
Collapse
Affiliation(s)
- Jean-François Chatillon
- University of Rouen Rouen, France ; Institut National de la Santé et de la Recherche Médicale (INSERM) U905 Rouen, France
| | - Mohamad Hamieh
- University of Rouen Rouen, France ; INSERM U1079 Rouen, France
| | - Florence Bayeux
- Institut National de la Santé et de la Recherche Médicale (INSERM) U905 Rouen, France
| | - Claire Abasq
- University of Rouen Rouen, France ; Institut National de la Santé et de la Recherche Médicale (INSERM) U905 Rouen, France ; Rouen University Hospital Rouen, France
| | | | | | - Florian Guisier
- University of Rouen Rouen, France ; Institut National de la Santé et de la Recherche Médicale (INSERM) U905 Rouen, France ; Rouen University Hospital Rouen, France
| | - Jean-Baptiste Latouche
- University of Rouen Rouen, France ; INSERM U1079 Rouen, France ; Rouen University Hospital Rouen, France
| | - Philippe Musette
- University of Rouen Rouen, France ; Institut National de la Santé et de la Recherche Médicale (INSERM) U905 Rouen, France ; Rouen University Hospital Rouen, France
| |
Collapse
|
43
|
Charbit L, Mahe E, Phan A, Droitcourt C, Boralevi F, Puzenat E, Abasq C, Aubert H, Barbarot S, Avenel-Audran M, Rodriguez L, Begon E, Mallet S, Balguerie X, Aubin F, Piram M, Souillet AL, Maruani A, Plantin P, Bourrat E, Lacour JP, Chiaverini C, Mazereeuw-Hautier J, Labreze C, Lasek A, Fleuret C, Kupfer I, Hadj-Rabia S, Bursztejn AC. Traitements systémiques du psoriasis de l’enfant : étude multicentrique nationale chez 140 enfants. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
44
|
Misery L, Legoupil D, Schollhammer M, Brenaut E, Abasq C, Roguedas-Contios AM, Chastaing M. [The announcement of bad news in dermatology]. Ann Dermatol Venereol 2014; 141:729-35. [PMID: 25442480 DOI: 10.1016/j.annder.2014.09.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- L Misery
- Service de dermatologie, CHU, 2, avenue Foch, 29200 Brest, France; Groupe psychodermatologie, société française de dermatologie, 25, rue la Boétie, 75008 Paris, France.
| | - D Legoupil
- Service de dermatologie, CHU, 2, avenue Foch, 29200 Brest, France
| | - M Schollhammer
- Service de dermatologie, CHU, 2, avenue Foch, 29200 Brest, France; Groupe psychodermatologie, société française de dermatologie, 25, rue la Boétie, 75008 Paris, France
| | - E Brenaut
- Service de dermatologie, CHU, 2, avenue Foch, 29200 Brest, France
| | - C Abasq
- Service de dermatologie, CHU, 2, avenue Foch, 29200 Brest, France
| | | | - M Chastaing
- Groupe psychodermatologie, société française de dermatologie, 25, rue la Boétie, 75008 Paris, France; Unité de psychologie médicale, CHU, 2, avenue Foch, 29200 Brest, France
| |
Collapse
|
45
|
Picard D, Bénichou J, Sin C, Abasq C, Houivet E, Koning R, Cribier A, Veber B, Dujardin F, Eltchaninoff H, Joly P. Increased prevalence of psoriasis in patients with coronary artery disease: results from a case-control study. Br J Dermatol 2014; 171:580-7. [PMID: 24904002 DOI: 10.1111/bjd.13155] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/25/2014] [Indexed: 01/08/2023]
Abstract
BACKGROUND The incidence of myocardial events has been reported to be increased in patients with psoriasis. OBJECTIVES To investigate whether psoriasis is an independent risk factor for coronary artery disease (CAD). METHODS We compared the prevalence of psoriasis between case patients with a diagnosis of CAD based on coronary angiography findings and control patients with no CAD referred to the emergency surgery department for an acute noncardiovascular condition. Case and control patients were examined for the presence of psoriasis by two dermatologists. The prevalence of psoriasis was compared among patients with CAD according to CAD severity. Five-hundred cases and 500 age- and sex-matched controls were included. RESULTS Using matched univariate analysis, the prevalence of psoriasis was about twofold higher in CAD case patients than in control patients [8·0% vs. 3·4%, odds ratio (OR) 2·64; 95% confidence interval (CI) 1·42-4·88]. Using unconditional multivariate analysis, the association of psoriasis with CAD appeared to be borderline significant (OR 1·84; 95% CI 0·99-3·40). Psoriasis in patients with CAD was significantly associated with three-vessel involvement relative to one-or two-vessel involvement (13·1% vs. 6·1%; OR 3·07; 95% CI 1·50-6·25). CONCLUSIONS The prevalence of psoriasis is twofold higher in patients with CAD than in control patients without CAD. It is associated with a more severe coronary artery involvement.
Collapse
Affiliation(s)
- D Picard
- Department of Dermatology, Inserm U905, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Normandy, Rouen, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Coquart N, Roguedas AM, Abasq C, Misery L. Urticaire superficielle au cours des angio-œdèmes à bradykinine. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Uguen A, Talagas M, Quintin-Roué I, Abasq C, Coat C, Charles-Pétillon F, De Braekeleer M, Marcorelles P. [A silent-growing and fast-killing melanoma in a teenager]. Ann Pathol 2012; 32:254-8. [PMID: 23010398 DOI: 10.1016/j.annpat.2012.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2012] [Revised: 05/20/2012] [Accepted: 06/21/2012] [Indexed: 10/28/2022]
Abstract
Malignant melanoma is a relatively rare but potentially aggressive tumor in children and adolescents. We report the case of a metastatic malignant melanoma in a 17-year-old girl, first diagnosed on cytological features of a fine-needle lymph node aspiration and then histologically confirmed by both examination of the metastatic adenopathy and a clinically harmless skin lesion of the scalp, which harbored focal microscopic pattern of melanoma. A fluorescent in situ hybridization study revealed that both metastatic and primary cutaneous tumours contained the same and pejorative chromosomal aberration consisting in CCND1 amplification (11q13). This observation raises actual limits and challenges in the fields of diagnosis and treatment of fast-killing melanomas.
Collapse
Affiliation(s)
- Arnaud Uguen
- Service d'anatomie pathologique, pôle biologie-pathologie, CHRU de Brest, 2, avenue Foch, 29609 Brest cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Ameline M, Oillic H, Misery L, Abasq C. Onychomadèse secondaire à une candidose congénitale cutanée. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
49
|
Eusen M, Abasq C, Lemasson G, Revert K, Misery L. Hidradénite plantaire et mucoviscidose. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Abasq C. [The various ages of our skin]. Soins 2010:30-31. [PMID: 20963974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
From the day we are born, our skin is exposed to an unknown environment. Its development is predominantly based on characteristics which are inherent to the various age phases of life. Totally covering a human being, it acts as a protector throughout its lifetime, without ever being protected itself.
Collapse
Affiliation(s)
- Claire Abasq
- Hôpital Morvan, Centre hospitalier régional universitaire, (CHRU), Brest.
| |
Collapse
|